[ad_1]
– Results were simultaneously presented today in a late breaker at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22) in Washington, DC
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced publication of results from the phase 1 APOLLO trial of SLN360, an siRNA targeting lipoprotein(a) (“Lp(a)”), in the latest issue of the Journal of the American Medical Association (JAMA), linked here.
Published by the American Medical Association (AMA), JAMA is the most widely circulated medical journal in the world, with over 55 million article views and downloads annually, and is among the most frequently cited medical and science journals.
The paper, authored by senior medical and scientific experts from both Silence and leading cardiology centers, showed that SLN360 reduced blood levels of Lp(a), a key genetic risk factor for heart disease, by up to 98% in healthy adults with elevated Lp (a).
The results were simultaneously presented today in a late breaker at the American College of Cardiology’s 71st Annual Scientific Session & Expo (ACC.22) in Washington, DC
About SLN360
Silence’s wholly owned lead product candidate, SLN360, is a gene ‘silencing’ therapy – one that is designed to temporarily block a specific gene’s message that would otherwise trigger an unwanted effect. In this case, it aims to ‘silence’ LPA, a gene that tells the body to make a specific protein that is only found in …
Full story available on Benzinga.com
[ad_2]
Source link
